Related references
Note: Only part of the references are listed.Adjunct antibiotic combination therapy for steroid-refractory or -dependent ulcerative colitis: an open-label multicentre study
K. Kato et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
The Treatment-Naive Microbiome in New-Onset Crohn's Disease
Dirk Gevers et al.
CELL HOST & MICROBE (2014)
Drosophila as a model for intestinal dysbiosis and chronic inflammatory diseases
Kyung-Ah Lee et al.
DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY (2014)
Is Rifaximin Effective in Maintaining Remission in Crohn's Disease?
Anca Olivia Jigaranu et al.
DIGESTIVE DISEASES (2014)
Pregnane X receptor agonists enhance intestinal epithelial wound healing and repair of the intestinal barrier following the induction of experimental colitis
Joshua Terc et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2014)
The Microbiome in Inflammatory Bowel Disease: Current Status and the Future Ahead
Aleksandar D. Kostic et al.
GASTROENTEROLOGY (2014)
Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI)
Pieter Dewint et al.
GUT (2014)
Challenges in Designing a National Surveillance Program for Inflammatory Bowel Disease in the United States
Millie D. Long et al.
INFLAMMATORY BOWEL DISEASES (2014)
Rifaximin: beyond the traditional antibiotic activity
Fiorella Calanni et al.
JOURNAL OF ANTIBIOTICS (2014)
Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature
Yael Haberman et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Combination of oral antibiotics may be effective in severe pediatric ulcerative colitis: A preliminary report
Dan Turner et al.
JOURNAL OF CROHNS & COLITIS (2014)
National estimates of the burden of inflammatory bowel disease among racial and ethnic groups in the United States
Geoffrey C. Nguyen et al.
JOURNAL OF CROHNS & COLITIS (2014)
The role of diet on intestinal microbiota metabolism: downstream impacts on host immune function and health, and therapeutic implications
Jason R. Goldsmith et al.
JOURNAL OF GASTROENTEROLOGY (2014)
Complex host genetics influence the microbiome in inflammatory bowel disease
Dan Knights et al.
GENOME MEDICINE (2014)
Antibiotics, Probiotics and Prebiotics in IBD
Charles N. Bernstein
NUTRITION, GUT MICROBIOTA AND IMMUNITY: THERAPEUTIC TARGETS FOR IBD (2014)
Rifaximin Resistance in Escherichia coli Associated with Inflammatory Bowel Disease Correlates with Prior Rifaximin Use, Mutations in rpoB, and Activity of Phe-Arg-β-Naphthylamide-Inhibitable Efflux Pumps
Vishesh Kothary et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Pregnane X Receptor (PXR) at the Crossroads of Human Metabolism and Disease
Ioannis Koutsounas et al.
CURRENT DRUG METABOLISM (2013)
Recent Trends in the Prevalence of Crohn's Disease and Ulcerative Colitis in a Commercially Insured US Population
Michael D. Kappelman et al.
DIGESTIVE DISEASES AND SCIENCES (2013)
Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome
Dan Knights et al.
GUT (2013)
Bile Acid Malabsorption Deactivates Pregnane X Receptor in Patients with Crohn's Disease
Junichi Iwamoto et al.
INFLAMMATORY BOWEL DISEASES (2013)
Multidrug Resistance Is Common in Escherichia coli Associated with Ileal Crohn's Disease
Belgin Dogan et al.
INFLAMMATORY BOWEL DISEASES (2013)
Rifaximin-Mediated Changes to the Epithelial Cell Proteome: 2-D Gel Analysis
Caroline Schrodt et al.
PLOS ONE (2013)
From genetics of inflammatory bowel disease towards mechanistic insights
Daniel B. Graham et al.
TRENDS IN IMMUNOLOGY (2013)
Use of antibiotics in the treatment of Crohn's disease
Maria Lia Scribano et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2013)
The role of antimicrobials in Crohn's disease
Pramodini B. Kale-Pradhan et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2013)
Rifaximin-Extended Intestinal Release Induces Remission in Patients With Moderately Active Crohn's Disease
Cosimo Prantera et al.
GASTROENTEROLOGY (2012)
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease
Luke Jostins et al.
NATURE (2012)
Acute and chronic pouchitis-pathogenesis, diagnosis and treatment
Bo Shen
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2012)
Pregnane X receptor as a target for treatment of inflammatory bowel disorders
Jie Cheng et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2012)
Antibiotic Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
Khurram J. Khan et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Inhibition of NF-κB by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells
Andrea Mencarelli et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2011)
Disease Phenotype and Genotype Are Associated with Shifts in Intestinal-associated Microbiota in Inflammatory Bowel Diseases
Daniel N. Frank et al.
INFLAMMATORY BOWEL DISEASES (2011)
Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee
Asher Kornbluth et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Newly Developed Antibiotic Combination Therapy for Ulcerative Colitis: A Double-Blind Placebo-Controlled Multicenter Trial
Toshifumi Ohkusa et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Pretreatment of Epithelial Cells with Rifaximin Alters Bacterial Attachment and Internalization Profiles
Eric L. Brown et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Pregnane-X-receptor mediates the anti-inflammatory activities of rifaximin on detoxification pathways in intestinal epithelial cells
Andrea Mencarelli et al.
BIOCHEMICAL PHARMACOLOGY (2010)
The role of mucosal immunity and host genetics in defining intestinal commensal bacteria
Jonathan Hansen et al.
CURRENT OPINION IN GASTROENTEROLOGY (2010)
Genetics and Environmental Interactions Shape the Intestinal Microbiome to Promote Inflammatory Bowel Disease Versus Mucosal Homeostasis
R. Balfour Sartor
GASTROENTEROLOGY (2010)
Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system
Simone Maccaferri et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
A. Dignass et al.
JOURNAL OF CROHNS & COLITIS (2010)
Therapeutic Role of Rifaximin in Inflammatory Bowel Disease: Clinical Implication of Human Pregnane X Receptor Activation
Jie Cheng et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Management of Crohn's Disease in Adults
Gary R. Lichtenstein et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Commensal bacteria, traditional and opportunistic pathogens, dysbiosis and bacterial killing in inflammatory bowel diseases
Christopher D. Packey et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2009)
European evidence-based Consensus on the management of ulcerative colitis: Current management
S. P. L. Travis et al.
JOURNAL OF CROHNS & COLITIS (2008)
PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics
Bin Zhang et al.
PHARMACOGENOMICS (2008)
Rifaximin is a gut-specific human pregnane X receptor activator
Xiaochao Ma et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Pregnane X receptor activation ameliorates DSS-induced inflammatory bowel disease via inhibition of NF-κB target gene expression
Yatrik M. Shah et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2007)
Bacterial translocation: Overview of mechanisms and clinical impact
Silvio Balzan et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2007)
Mutual repression between steroid and xenobiotic receptor and NF-κB signaling pathways links xenobiotic metabolism and inflammation
Changcheng Zhou et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis
RB Sartor
NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY (2006)
Rifaximin for active ulcerative colitis
M Guslandi et al.
INFLAMMATORY BOWEL DISEASES (2006)
Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic
C Scarpignato et al.
DIGESTION (2006)
Diversity of the human intestinal microbial flora
PB Eckburg et al.
SCIENCE (2005)
The mdr1a(-/-) mouse model of spontaneous colitis - A relevant and appropriate animal model to study inflammatory bowel disease
JN Wilk et al.
IMMUNOLOGIC RESEARCH (2005)
Rifaximin, a poorly absorbed antibiotic: Pharmacology and clinical potential
C Scarpignato et al.
CHEMOTHERAPY (2005)
Loss of detoxification in inflammatory bowel disease: Dysregulation of pregnane X receptor target genes
T Langmann et al.
GASTROENTEROLOGY (2004)
Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis
M Schwab et al.
GASTROENTEROLOGY (2003)
Bacterial translocation in patients with Crohn's disease undergoing surgery
Y Takesue et al.
DISEASES OF THE COLON & RECTUM (2002)
Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis
P Brigidi et al.
JOURNAL OF CHEMOTHERAPY (2002)
Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis
S Fiorucci et al.
DIGESTION (2002)
Effect of rifaximin on intestinal bacterial overgrowth in Crohn's disease as assessed by the H-2-glucose breath test
L Biancone et al.
CURRENT MEDICAL RESEARCH AND OPINION (2000)
Share Paper
